TWI800478B - 三重升糖素/glp-1/gip受體促效劑 - Google Patents

三重升糖素/glp-1/gip受體促效劑 Download PDF

Info

Publication number: TWI800478B
Authority: TW; Taiwan
Prior art keywords: glp; receptor agonist; gip receptor; glucagon; triple
Prior art date: 2015-12-31

Application number

TW105144155A

Other languages

English (en)

Other versions

TW201730207A (zh

Inventor

吳宜林

李鍾錫

朴永振

林昌基

鄭聖燁

權世昌

Original Assignee

南韓商韓美藥品股份有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-31

Filing date

2016-12-30

Publication date

2023-05-01

2016-12-30 Application filed by 南韓商韓美藥品股份有限公司 filed Critical 南韓商韓美藥品股份有限公司

2017-09-01 Publication of TW201730207A publication Critical patent/TW201730207A/zh

2023-05-01 Application granted granted Critical

2023-05-01 Publication of TWI800478B publication Critical patent/TWI800478B/zh

Links

101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Mycology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

TW105144155A 2015-12-31 2016-12-30 三重升糖素/glp-1/gip受體促效劑 TWI800478B (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
KR20150191082		2015-12-31
KR10-2015-0191082		2015-12-31
KR10-2016-0163737		2016-12-02
KR20160163737		2016-12-02

Publications (2)

Publication Number	Publication Date
TW201730207A TW201730207A (zh)	2017-09-01
TWI800478B true TWI800478B (zh)	2023-05-01

Family

ID=59225193

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
TW105144154A TWI731015B (zh)	2015-12-31	2016-12-30	三重升糖素/ｇｌｐ-１/ｇｉｐ受體促效劑之長效接合物
TW111101118A TWI807580B (zh)	2015-12-31	2016-12-30	三重升糖素/glp-1/gip 受體促效劑
TW105144155A TWI800478B (zh)	2015-12-31	2016-12-30	三重升糖素/glp-1/gip受體促效劑
TW112108994A TWI877582B (zh)	2015-12-31	2016-12-30	三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
TW105144154A TWI731015B (zh)	2015-12-31	2016-12-30	三重升糖素/ｇｌｐ-１/ｇｉｐ受體促效劑之長效接合物
TW111101118A TWI807580B (zh)	2015-12-31	2016-12-30	三重升糖素/glp-1/gip 受體促效劑

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW112108994A TWI877582B (zh)	2015-12-31	2016-12-30	三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑

Country Status (32)

Country	Link
US (6)	US10370426B2 (zh)
EP (3)	EP3398961B1 (zh)
JP (5)	JP6712323B2 (zh)
KR (8)	KR20170080521A (zh)
CN (6)	CN115920077B (zh)
AU (4)	AU2016382394B2 (zh)
BR (2)	BR112018013530A2 (zh)
CA (2)	CA3010182A1 (zh)
CL (6)	CL2018001776A1 (zh)
CO (2)	CO2018006986A2 (zh)
CR (2)	CR20180380A (zh)
DK (1)	DK3398961T3 (zh)
DO (2)	DOP2018000157A (zh)
EA (2)	EA038544B1 (zh)
EC (2)	ECSP18053053A (zh)
ES (1)	ES2925098T3 (zh)
HK (1)	HK1258177A1 (zh)
HR (1)	HRP20220995T1 (zh)
HU (1)	HUE059737T2 (zh)
IL (2)	IL260310B2 (zh)
MX (2)	MX2018008128A (zh)
PE (2)	PE20250556A1 (zh)
PH (2)	PH12018501411B1 (zh)
PL (1)	PL3398961T3 (zh)
PT (1)	PT3398961T (zh)
RS (1)	RS63541B1 (zh)
SA (2)	SA518391891B1 (zh)
SG (2)	SG11201805586SA (zh)
TN (2)	TN2018000228A1 (zh)
TW (4)	TWI731015B (zh)
WO (2)	WO2017116205A1 (zh)
ZA (2)	ZA201804997B (zh)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20130049671A (ko)	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
MX387560B (es) *	2014-03-31	2025-03-18	Hanmi Pharmaceutical Co Ltd	Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
TN2017000271A1 (en)	2014-12-30	2018-10-19	Hanmi Pharm Ind Co Ltd	Glucagon derivative having improved stability
ES2973017T3 (es)	2015-06-30	2024-06-18	Hanmi Pharmaceutical Co Ltd	Derivado del glucagón y una composición que comprende un conjugado de acción prolongada del mismo
HUE059737T2 (hu)	2015-12-31	2022-12-28	Hanmi Pharm Ind Co Ltd	Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor
CA3029518A1 (en)	2016-06-29	2018-01-04	Hanmi Pharm. Co., Ltd.	Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
BR112019016077A2 (pt)	2017-02-03	2020-03-31	Hanmi Pharm. Co., Ltd.	Conjugado da fórmula 1, método para preparar o conjugado, preparação de atuação longa, preparação para prevenir ou tratar diabetes e método para tratar diabetes
CN110545852B (zh)	2017-02-07	2023-05-26	韩美药品株式会社	非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法
BR112019016139A2 (pt)	2017-02-08	2020-04-07	Bristol-Myers Squibb Company	polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
JOP20180028A1 (ar)	2017-03-31	2019-01-30	Takeda Pharmaceuticals Co	مركب ببتيد
AR113486A1 (es) *	2017-12-21	2020-05-06	Lilly Co Eli	Análogos de incretina y sus usos
TWI767095B (zh)	2017-12-21	2022-06-11	美商美國禮來大藥廠	腸促胰島素(incretin)類似物及其用途
CN109239346B (zh) *	2018-10-31	2019-10-11	中国药科大学	一组代谢标志物在代谢综合征早期诊断方面的应用
EP3900735A4 (en) *	2018-12-21	2022-09-07	Hanmi Pharm. Co., Ltd.	PHARMACEUTICAL COMPOSITION WITH INSULIN AND TRIPLE AGONOISTS WITH ACTIVITY AGAINST ALL GLUCAGON AND GLP-1 AND GIP RECEPTORS
WO2020167010A1 (ko)	2019-02-15	2020-08-20	한미정밀화학주식회사	생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
WO2020214012A1 (ko) *	2019-04-19	2020-10-22	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) *	2019-04-19	2020-10-22	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
CN111944055B (zh) *	2019-05-16	2022-08-02	浙江道尔生物科技有限公司	一种治疗代谢疾病的融合蛋白
EP4311578A3 (en) *	2019-06-28	2024-04-10	Hanmi Pharm. Co., Ltd.	Triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors for treating liver disease
MY201700A (en)	2019-08-19	2024-03-13	Lilly Co Eli	Methods of making incretin analogs
US20230000950A1 (en) *	2019-10-04	2023-01-05	Hanmi Pharm. Co., Ltd.	Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
MX2022005661A (es)	2019-11-11	2022-09-07	Boehringer Ingelheim Int	Agonistas del receptor npy2.
TWI795698B (zh)	2019-12-18	2023-03-11	美商美國禮來大藥廠	腸促胰島素(incretin)類似物及其用途
CN111040022B (zh) *	2019-12-23	2021-12-14	万新医药科技(苏州)有限公司	针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
CN113597434B (zh)	2019-12-31	2022-07-01	北京质肽生物医药科技有限公司	Glp-1和gdf15的融合蛋白以及其缀合物
EP4104849A4 (en) *	2020-01-13	2024-03-27	Hanmi Pharm. Co., Ltd.	THERAPEUTIC USE OF A LONG-ACTING CONJUGATE OF A TRIPLE AGONIST WITH ACTIVITY RELATED TO GLUCAGON AND GLP-1 AND GIP RECEPTORS AGAINST LUNG DISEASE
MX2022009524A (es)	2020-02-07	2023-01-11	Gasherbrum Bio Inc	Agonistas heterociclicos de glp-1.
WO2021215801A1 (ko) *	2020-04-20	2021-10-28	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2021235916A1 (ko) *	2020-05-22	2021-11-25	한미약품 주식회사	글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제
KR20210144608A (ko) *	2020-05-22	2021-11-30	한미약품 주식회사	액상 제제
EP4183419A4 (en) *	2020-07-17	2025-04-02	Hanmi Pharm. Co., Ltd.	THERAPEUTIC USE OF A COMBINATION WITH A LONG-ACTING TRIPLE AGONIST CONJUGATE OR TRIPLE AGONIST
WO2022028572A1 (en)	2020-08-06	2022-02-10	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
WO2022029231A1 (en)	2020-08-07	2022-02-10	Boehringer Ingelheim International Gmbh	Soluble npy2 receptor agonists
CA3187742A1 (en)	2020-08-14	2022-02-17	Seungjae Baek	Pharmaceutical composition comprising long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
MX2023001601A (es)	2020-08-14	2023-03-07	Hanmi Pharmaceutical Co Ltd	Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip.
CN116600831A (zh) *	2020-09-25	2023-08-15	韩美药品株式会社	对胰高血糖素、glp-1和glp受体全部具有活性的三重激动剂或其缀合物用于神经变性疾病的治疗用途
JP2023543042A (ja) *	2020-09-25	2023-10-12	ハンミファーマシューティカルカンパニーリミテッド	グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体またはその結合体を含む骨疾患に対する予防または治療用薬学的組成物
US20230372448A1 (en)	2020-09-25	2023-11-23	Hanmi Pharm. Co., Ltd.	Therapeutic use of long-acting conjugate of triple agonist acting on all of glucagon, glp-1 and gip receptors against multiple sclerosis
CA3193453A1 (en)	2020-09-30	2022-04-07	Beijing Ql Biopharmaceutical Co., Ltd.	Polypeptide conjugates and methods of uses
US20230381333A1 (en) *	2020-10-16	2023-11-30	Hanmi Pharm. Co., Ltd.	Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating vasculitis
EP4230217A4 (en) *	2020-10-16	2024-11-20	Hanmi Pharm. Co., Ltd.	PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH LUPUS COMPRISING A GIP DERIVATIVE OR A CORRESPONDING LONG-ACTING CONJUGATE
WO2022080991A1 (ko)	2020-10-16	2022-04-21	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도
EP4230639A4 (en) *	2020-10-16	2025-01-15	Hanmi Pharm. Co., Ltd.	GIP DERIVATIVE, LONG-ACTING CONJUGATE THEREOF AND PHARMACEUTICAL COMPOSITION THEREOF
JP2023546088A (ja) *	2020-10-16	2023-11-01	ハンミファーマシューティカルズカンパニーリミテッド	グルカゴン／ｇｌｐ－１／ｇｉｐ三重作用剤またはその持続型結合体を含むループス関連疾患の予防用または治療用の薬学的組成物
JP2023550594A (ja)	2020-10-30	2023-12-04	ノヴォノルディスクアー／エス	Ｇｌｐ－１、ｇｉｐ、およびグルカゴン受容体三重作動薬
KR20230116894A (ko) *	2020-12-02	2023-08-04	둥바오 퍼플 스타 (항저우) 바이오파마슈티컬 컴퍼니 리미티드	락탐 변형을 포함한 폴리펩타이드계 화합물
KR20220092442A (ko) *	2020-12-24	2022-07-01	한미약품 주식회사	신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도
WO2022159395A1 (en)	2021-01-20	2022-07-28	Viking Therapeutics, Inc.	Compositions and methods for the treatment of metabolic and liver disorders
CN116847868A (zh) *	2021-01-29	2023-10-03	韩美药品株式会社	用于预防或治疗肺部疾病的包括gip衍生物或其长效共轭物的药学组合物
CN117062618B (zh) *	2021-05-26	2026-01-02	联邦生物科技(珠海横琴)有限公司	多激动剂及其应用
KR20230004135A (ko) *	2021-06-30	2023-01-06	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
TW202313667A (zh) *	2021-07-30	2023-04-01	大陸商南京明德新藥研發有限公司	含內醯胺橋的多肽化合物
EP4259647A4 (en)	2021-09-15	2025-03-26	Viking Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES
KR20230095665A (ko) *	2021-12-22	2023-06-29	한미약품 주식회사	간 표적 약물 및 이의 용도
JP2025509281A (ja)	2022-03-09	2025-04-11	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環式ｇｌｐ－１アゴニスト
JP2025510741A (ja)	2022-03-21	2025-04-15	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環式ｇｌｐ－１アゴニスト
JP2025512832A (ja)	2022-03-30	2025-04-22	ベイジンキューエルバイオファーマシューティカルカンパニー，リミテッド	ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
EP4508047A1 (en)	2022-04-14	2025-02-19	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
CA3257100A1 (en) *	2022-05-27	2023-11-30	D&D Pharmatech Inc.	PEPTIDE COMPOSITIONS AND THEIR METHODS OF USE
WO2024136573A1 (ko) *	2022-12-23	2024-06-27	한미약품 주식회사	신규한 glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 비만의 예방 또는 치료용 약학적 조성물
US20240270821A1 (en)	2023-01-31	2024-08-15	Eli Lilly And Company	Gip/glp1/gcg tri-receptor agonists and uses thereof
CN121285571A (zh)	2023-06-09	2026-01-06	太阳医药工业有限公司	Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
KR20250177375A (ko) *	2024-06-13	2025-12-23	한미약품 주식회사	Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물
WO2025259063A1 (ko) *	2024-06-13	2025-12-18	한미약품 주식회사	Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 당뇨 예방 또는 치료용 약학적 조성물
CN120189527A (zh) *	2025-05-27	2025-06-24	南方医科大学第三附属医院（广东省骨科研究院）	一种多肽与抗体Fc片段的偶联物、药物组合物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130116173A1 (en) *	2010-12-22	2013-05-09	Indiana University Research And Technology Corporation	Glucagon Analogs Exhibiting GIP Receptor Activity
US20130203659A1 (en) *	2006-04-20	2013-08-08	Leslie P. Miranda	Glp-1 compounds
US20140011738A1 (en) *	2012-06-21	2014-01-09	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5476304A (en)	1977-11-29	1979-06-18	Tokyo Printing Ink Mfg Co Ltd	Ink
US5408037A (en)	1991-01-17	1995-04-18	Zymogenetics, Inc.	Methods for detecting glucagon antagonists
GB9423277D0 (en)	1994-11-18	1995-01-11	Univ Nottingham	Pulsed laser deposition of coatings
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en)	1996-03-18	2001-01-18	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
DE60044041D1 (de) *	1999-01-14	2010-04-29	Amylin Pharmaceuticals Inc	Exendine zur Glucagon Suppression
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
ES2321439T3 (es) *	2000-06-16	2009-06-05	ELI LILLY & COMPANY	Analogos del peptido-1 similar a glucagon.
ATE408414T1 (de) *	2001-07-31	2008-10-15	Us Gov Health & Human Serv	Glp 1 exendin 4 peptidanaloga und deren verwendungen
HRP20050683A2 (en) *	2003-03-19	2006-07-31	Eli Lilly And Company	Polyethylene glycol linked glp-1 compounds
JP2007537981A (ja) *	2003-09-19	2007-12-27	ノボ　ノルディスク　アクティーゼルスカブ	新規の血漿タンパク質親和性タグ
US8263084B2 (en)	2003-11-13	2012-09-11	Hanmi Science Co., Ltd	Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP1682582B1 (en)	2003-11-13	2011-08-31	Hanmi Holdings Co., Ltd	Method for the mass production of immunoglobulin constant region
WO2007124045A2 (en) *	2006-04-20	2007-11-01	Ampla Pharmaceuticals, Inc.	Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
US20090098130A1 (en)	2007-01-05	2009-04-16	Bradshaw Curt W	Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CN101578102B (zh)	2007-01-05	2013-07-17	印第安纳大学研究及科技有限公司	在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
JP2008169195A (ja)	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
AU2008216265B2 (en)	2007-02-15	2014-04-03	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
US7994122B2 (en)	2007-06-15	2011-08-09	Zealand Pharma A/S	Glucagon analogues
DK2172479T3 (en)	2007-06-19	2016-12-19	Glytech Inc	GLP-1 peptide having the sugar chain attached thereto
WO2009030738A1 (en)	2007-09-05	2009-03-12	Novo Nordisk A/S	Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20110065633A1 (en)	2008-01-30	2011-03-17	Indiana University Research And Technology Corporation	Ester-based peptide prodrugs
CL2009001425A1 (es)	2008-06-17	2010-04-30	Univ Indiana Res & Tech Corp	Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
CN102088989B (zh)	2008-06-17	2014-11-26	印第安纳大学研究及科技有限公司	在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
PA8830501A1 (es) *	2008-06-17	2010-07-27	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
MX2011013625A (es)	2009-06-16	2012-01-20	Univ Indiana Res & Tech Corp	Compuestos glucagon activo de receptor de gip.
EA022816B1 (ru)	2009-07-13	2016-03-31	Зилэнд Фарма А/С	Ацилированные аналоги глюкагона
GB0917072D0 (en)	2009-09-29	2009-11-11	Univ Ulster	Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
CA2786934A1 (en)	2010-01-20	2011-07-28	Zealand Pharma A/S	Treatment of cardiac conditions
US8551946B2 (en) *	2010-01-27	2013-10-08	Indiana University Research And Technology Corporation	Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
JP5812627B2 (ja) *	2010-03-10	2015-11-17	公益財団法人相模中央化学研究所	改良Ｆｃ受容体およびその製造方法
BR112012024379A2 (pt)	2010-03-26	2017-01-10	Novo Nordisk As	"peptídeos glucagon, seu uso, bem como composição farmacêutica"
CN103179976A (zh)	2010-05-13	2013-06-26	印第安纳大学研究及科技有限公司	呈现g蛋白偶联受体活性的胰高血糖素超家族肽
KR101382593B1 (ko)	2010-07-21	2014-04-10	한미사이언스 주식회사	신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012150503A2 (en)	2011-05-03	2012-11-08	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
DK2710031T3 (en)	2011-05-18	2018-01-02	Mederis Diabetes Llc	IMPROVED PEPTID MEDICINALS FOR INSULIN RESISTANCE
UA113626C2 (xx) *	2011-06-02	2017-02-27		Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PE20181299A1 (es)	2011-06-10	2018-08-09	Hanmi Science Co Ltd	Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
SMT201900078T1 (it)	2011-06-17	2019-02-28	Hanmi Science Co Ltd	Un coniugato comprendente oxintomodulina e un frammento di immunoglobulina, e suo uso
CA2839867A1 (en) *	2011-06-22	2012-12-27	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
JP6179864B2 (ja) *	2011-06-22	2017-08-16	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
WO2013004983A1 (en)	2011-07-04	2013-01-10	Imperial Innovations Limited	Novel compounds and their effects on feeding behaviour
JP6324315B2 (ja)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
US9745359B2 (en)	2012-05-18	2017-08-29	Adda Biotech Inc.	Protein and protein conjugate for diabetes treatment, and applications thereof
CA2877363A1 (en) *	2012-06-21	2013-12-27	Indiana University Research And Technology Corporation	Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
PT2864350T (pt) *	2012-06-21	2018-05-14	Hoffmann La Roche	Análogos do glucagon que apresentam uma atividade sobre o recetor do gip
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es)	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092873A1 (es) *	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
AU2013342321B2 (en)	2012-11-06	2017-09-28	Hanmi Pharm. Co., Ltd.	Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR102213907B1 (ko)	2012-11-20	2021-02-09	메더리스 다이어비티즈, 엘엘씨	인슐린 저항성에 대한 개선된 펩티드 약제
EP2922877B1 (en) *	2012-11-20	2018-09-05	Eumederis Pharmaceuticals, Inc.	Improved peptide pharmaceuticals
CA2894765A1 (en) *	2012-12-21	2014-06-26	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
JP2016521253A (ja) *	2013-03-15	2016-07-21	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	持続性作用を有するプロドラッグ
BR112015025464A2 (pt)	2013-04-18	2017-10-10	Novo Nordisk As	coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
HK1226084A1 (zh)	2013-08-16	2017-09-22	Medimmune Limited	用於治疗糖尿病的gip和glp-1受体双重激动剂
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP4212180A1 (en)	2013-12-18	2023-07-19	The Scripps Research Institute	Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR100639A1 (es)	2014-05-29	2016-10-19	Hanmi Pharm Ind Co Ltd	Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh)	2014-05-30	2020-02-11	南韓商韓美藥品股份有限公司	包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10232020B2 (en) *	2014-09-24	2019-03-19	Indiana University Research And Technology Corporation	Incretin-insulin conjugates
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
TN2017000271A1 (en)	2014-12-30	2018-10-19	Hanmi Pharm Ind Co Ltd	Glucagon derivative having improved stability
ES2973017T3 (es)	2015-06-30	2024-06-18	Hanmi Pharmaceutical Co Ltd	Derivado del glucagón y una composición que comprende un conjugado de acción prolongada del mismo
TW201718629A (zh)	2015-09-25	2017-06-01	韓美藥品股份有限公司	包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
WO2017095201A1 (ko)	2015-12-02	2017-06-08	한미약품 주식회사	지방산 유도체를 이용한 단백질 결합체 및 이의 제조방법
HUE059737T2 (hu) *	2015-12-31	2022-12-28	Hanmi Pharm Ind Co Ltd	Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor

2016
- 2016-12-30 HU HUE16882156A patent/HUE059737T2/hu unknown
- 2016-12-30 CA CA3010182A patent/CA3010182A1/en active Pending
- 2016-12-30 BR BR112018013530-5A patent/BR112018013530A2/pt active Search and Examination
- 2016-12-30 EA EA201891360A patent/EA038544B1/ru unknown
- 2016-12-30 KR KR1020160183499A patent/KR20170080521A/ko not_active Ceased
- 2016-12-30 CN CN202211656375.4A patent/CN115920077B/zh active Active
- 2016-12-30 JP JP2018534682A patent/JP6712323B2/ja active Active
- 2016-12-30 EP EP16882156.9A patent/EP3398961B1/en active Active
- 2016-12-30 RS RS20220774A patent/RS63541B1/sr unknown
- 2016-12-30 PL PL16882156.9T patent/PL3398961T3/pl unknown
- 2016-12-30 CR CR20180380A patent/CR20180380A/es unknown
- 2016-12-30 MX MX2018008128A patent/MX2018008128A/es unknown
- 2016-12-30 TN TNP/2018/000228A patent/TN2018000228A1/en unknown
- 2016-12-30 CN CN202211234307.9A patent/CN116063453A/zh active Pending
- 2016-12-30 EP EP16882157.7A patent/EP3398962A4/en active Pending
- 2016-12-30 TW TW105144154A patent/TWI731015B/zh active
- 2016-12-30 TW TW111101118A patent/TWI807580B/zh active
- 2016-12-30 CN CN201680082339.8A patent/CN109071624B/zh active Active
- 2016-12-30 EP EP21201279.3A patent/EP3985017A1/en active Pending
- 2016-12-30 HK HK19100534.2A patent/HK1258177A1/zh unknown
- 2016-12-30 DK DK16882156.9T patent/DK3398961T3/da active
- 2016-12-30 IL IL260310A patent/IL260310B2/en unknown
- 2016-12-30 AU AU2016382394A patent/AU2016382394B2/en active Active
- 2016-12-30 CN CN202211234594.3A patent/CN116063454A/zh active Pending
- 2016-12-30 PT PT168821569T patent/PT3398961T/pt unknown
- 2016-12-30 KR KR1020160183500A patent/KR20170080522A/ko not_active Ceased
- 2016-12-30 JP JP2018534662A patent/JP6712322B2/ja active Active
- 2016-12-30 AU AU2016382393A patent/AU2016382393B2/en active Active
- 2016-12-30 ES ES16882156T patent/ES2925098T3/es active Active
- 2016-12-30 TN TNP/2018/000231A patent/TN2018000231A1/en unknown
- 2016-12-30 SG SG11201805586SA patent/SG11201805586SA/en unknown
- 2016-12-30 WO PCT/KR2016/015555 patent/WO2017116205A1/ko not_active Ceased
- 2016-12-30 HR HRP20220995TT patent/HRP20220995T1/hr unknown
- 2016-12-30 WO PCT/KR2016/015554 patent/WO2017116204A1/ko not_active Ceased
- 2016-12-30 EA EA201891359A patent/EA038524B1/ru unknown
- 2016-12-30 CR CR20180381A patent/CR20180381A/es unknown
- 2016-12-30 CA CA3010265A patent/CA3010265C/en active Active
- 2016-12-30 BR BR112018013525-9A patent/BR112018013525A2/pt active Search and Examination
- 2016-12-30 MX MX2018008027A patent/MX2018008027A/es unknown
- 2016-12-30 PH PH1/2018/501411A patent/PH12018501411B1/en unknown
- 2016-12-30 CN CN202211287482.4A patent/CN116059389A/zh active Pending
- 2016-12-30 PH PH1/2018/501409A patent/PH12018501409B1/en unknown
- 2016-12-30 TW TW105144155A patent/TWI800478B/zh active
- 2016-12-30 PE PE2023002166A patent/PE20250556A1/es unknown
- 2016-12-30 IL IL260318A patent/IL260318B2/en unknown
- 2016-12-30 SG SG11201805573RA patent/SG11201805573RA/en unknown
- 2016-12-30 TW TW112108994A patent/TWI877582B/zh active
- 2016-12-30 PE PE2018001233A patent/PE20181494A1/es unknown
- 2016-12-30 CN CN201680082352.3A patent/CN108699125B/zh active Active
2018
- 2018-06-25 SA SA518391891A patent/SA518391891B1/ar unknown
- 2018-06-26 SA SA518391903A patent/SA518391903B1/ar unknown
- 2018-06-28 CL CL2018001776A patent/CL2018001776A1/es unknown
- 2018-06-28 DO DO2018000157A patent/DOP2018000157A/es unknown
- 2018-06-29 US US16/023,994 patent/US10370426B2/en active Active
- 2018-06-29 US US16/024,014 patent/US10400020B2/en active Active
- 2018-06-29 CL CL2018001795A patent/CL2018001795A1/es unknown
- 2018-06-29 DO DO2018000159A patent/DOP2018000159A/es unknown
- 2018-07-04 CO CONC2018/0006986A patent/CO2018006986A2/es unknown
- 2018-07-04 CO CONC2018/0006982A patent/CO2018006982A2/es unknown
- 2018-07-13 EC ECSENADI201853053A patent/ECSP18053053A/es unknown
- 2018-07-13 EC ECSENADI201853055A patent/ECSP18053055A/es unknown
- 2018-07-25 ZA ZA2018/04997A patent/ZA201804997B/en unknown
- 2018-07-25 ZA ZA2018/04998A patent/ZA201804998B/en unknown
2019
- 2019-01-31 US US16/263,469 patent/US10981967B2/en active Active
- 2019-03-29 US US16/370,057 patent/US11332508B2/en active Active
- 2019-05-27 KR KR1020190061852A patent/KR102367997B1/ko active Active
- 2019-05-27 KR KR1020190061853A patent/KR102401869B1/ko active Active
- 2019-06-04 AU AU2019203888A patent/AU2019203888B2/en active Active
- 2019-06-04 AU AU2019203891A patent/AU2019203891B2/en active Active
- 2019-08-29 KR KR1020190106690A patent/KR102179391B1/ko active Active
- 2019-08-29 KR KR1020190106691A patent/KR102179392B1/ko active Active
2020
- 2020-05-29 JP JP2020093915A patent/JP7526039B2/ja active Active
- 2020-05-29 JP JP2020093904A patent/JP7030894B2/ja active Active
- 2020-07-27 KR KR1020200093189A patent/KR102285377B1/ko active Active
- 2020-07-27 KR KR1020200093190A patent/KR102285378B1/ko active Active
- 2020-08-05 CL CL2020002033A patent/CL2020002033A1/es unknown
- 2020-08-05 CL CL2020002034A patent/CL2020002034A1/es unknown
2021
- 2021-02-26 US US17/187,098 patent/US20210188937A1/en not_active Abandoned
2022
- 2022-03-07 CL CL2022000557A patent/CL2022000557A1/es unknown
- 2022-03-07 CL CL2022000558A patent/CL2022000558A1/es unknown
- 2022-03-21 US US17/700,055 patent/US20220213164A1/en active Pending
- 2022-07-07 JP JP2022109549A patent/JP2022130723A/ja active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130203659A1 (en) *	2006-04-20	2013-08-08	Leslie P. Miranda	Glp-1 compounds
US20130116173A1 (en) *	2010-12-22	2013-05-09	Indiana University Research And Technology Corporation	Glucagon Analogs Exhibiting GIP Receptor Activity
US20140011738A1 (en) *	2012-06-21	2014-01-09	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity

Also Published As

Publication number	Publication date
KR20200096184A (ko)	2020-08-11
TW201730207A (zh)	2017-09-01
BR112018013525A2 (pt)	2018-12-04
KR102179391B1 (ko)	2020-11-16
JP6712322B2 (ja)	2020-06-17
US20190002520A1 (en)	2019-01-03
BR112018013530A2 (pt)	2018-12-04
KR20190060749A (ko)	2019-06-03
HUE059737T2 (hu)	2022-12-28
CN116063454A (zh)	2023-05-05
IL260310A (en)	2018-08-30
IL260310B2 (en)	2024-02-01
KR20170080522A (ko)	2017-07-10
PL3398961T3 (pl)	2022-09-26
KR102285378B1 (ko)	2021-08-04
DK3398961T3 (da)	2022-08-22
KR20190062344A (ko)	2019-06-05
JP2019504055A (ja)	2019-02-14
MX2018008027A (es)	2018-11-29
PH12018501409B1 (en)	2023-03-10
TW202330585A (zh)	2023-08-01
IL260318B2 (en)	2024-02-01
ECSP18053053A (es)	2018-07-31
TN2018000231A1 (en)	2019-10-04
EP3985017A1 (en)	2022-04-20
CL2020002034A1 (es)	2020-10-09
CO2018006982A2 (es)	2018-07-10
EA038544B1 (ru)	2021-09-13
CN115920077B (zh)	2025-07-04
AU2016382394A1 (en)	2018-08-02
PE20250556A1 (es)	2025-02-24
SG11201805573RA (en)	2018-07-30
TWI731015B (zh)	2021-06-21
EA201891359A1 (ru)	2019-01-31
KR102285377B1 (ko)	2021-08-04
JP6712323B2 (ja)	2020-06-17
CR20180380A (es)	2018-12-07
AU2016382393A1 (en)	2018-08-02
KR102367997B1 (ko)	2022-03-02
US10400020B2 (en)	2019-09-03
SG11201805586SA (en)	2018-07-30
EP3398961A1 (en)	2018-11-07
EA201891360A1 (ru)	2018-12-28
JP2020128428A (ja)	2020-08-27
CA3010182A1 (en)	2017-07-06
US20180311315A1 (en)	2018-11-01
AU2016382393B2 (en)	2019-07-04
EP3398961A4 (en)	2019-06-12
NZ744306A (en)	2024-05-31
CL2022000558A1 (es)	2022-09-23
US10370426B2 (en)	2019-08-06
EP3398962A1 (en)	2018-11-07
EA038524B1 (ru)	2021-09-09
CA3010265A1 (en)	2017-07-06
PE20181494A1 (es)	2018-09-18
CN109071624A (zh)	2018-12-21
JP2020171287A (ja)	2020-10-22
EP3398961B1 (en)	2022-06-29
CL2020002033A1 (es)	2020-10-09
EP3398962A4 (en)	2019-08-07
SA518391903B1 (ar)	2022-08-01
TN2018000228A1 (en)	2019-10-04
JP2022130723A (ja)	2022-09-06
US20190218269A1 (en)	2019-07-18
KR102179392B1 (ko)	2020-11-16
US20210188937A1 (en)	2021-06-24
AU2019203888A1 (en)	2019-06-20
CL2018001795A1 (es)	2018-08-10
CO2018006986A2 (es)	2018-07-10
TW202216748A (zh)	2022-05-01
RS63541B1 (sr)	2022-09-30
IL260318B1 (en)	2023-10-01
TW201737945A (zh)	2017-11-01
IL260310B1 (en)	2023-10-01
HK1258177A1 (zh)	2019-11-08
DOP2018000157A (es)	2018-10-15
CN108699125B (zh)	2022-10-28
PT3398961T (pt)	2022-09-05
WO2017116204A1 (ko)	2017-07-06
TWI877582B (zh)	2025-03-21
PH12018501411B1 (en)	2024-02-23
NZ744321A (en)	2024-04-26
HRP20220995T1 (hr)	2022-11-11
HK1255834A1 (zh)	2019-08-30
CA3010265C (en)	2025-05-20
KR20200095436A (ko)	2020-08-10
DOP2018000159A (es)	2018-09-30
AU2019203891B2 (en)	2021-05-13
PH12018501411A1 (en)	2019-04-08
CN116059389A (zh)	2023-05-05
KR20190105542A (ko)	2019-09-17
US10981967B2 (en)	2021-04-20
AU2016382394B2 (en)	2019-07-04
AU2019203891A1 (en)	2019-06-20
CL2022000557A1 (es)	2022-09-23
CN109071624B (zh)	2023-01-17
KR20190104958A (ko)	2019-09-11
KR20170080521A (ko)	2017-07-10
US20190153060A1 (en)	2019-05-23
TWI807580B (zh)	2023-07-01
JP7526039B2 (ja)	2024-07-31
JP2019504057A (ja)	2019-02-14
CN115920077A (zh)	2023-04-07
IL260318A (en)	2018-08-30
AU2019203888B2 (en)	2021-05-13
CR20180381A (es)	2019-01-14
CN116063453A (zh)	2023-05-05
PH12018501409A1 (en)	2019-04-08
SA518391891B1 (ar)	2021-07-12
WO2017116205A1 (ko)	2017-07-06
ES2925098T3 (es)	2022-10-13
ZA201804998B (en)	2019-05-29
ECSP18053055A (es)	2018-07-31
US11332508B2 (en)	2022-05-17
ZA201804997B (en)	2019-05-29
CN108699125A (zh)	2018-10-23
CL2018001776A1 (es)	2018-08-10
JP7030894B2 (ja)	2022-03-07
US20220213164A1 (en)	2022-07-07
MX2018008128A (es)	2018-12-06
KR102401869B1 (ko)	2022-05-25

Publication	Publication Date	Title
TWI800478B (zh)	2023-05-01	三重升糖素/glp-1/gip受體促效劑
IL287166A (en)	2021-12-01	A pyrazolopyridine derivative with an agonistic effect on the glp-1 receptor
IL285231A (en)	2021-09-30	Co-agonistic compounds for glucagon and glp-1
ZA201802371B (en)	2020-01-29	Glucagon receptor agonists
IL266985A (en)	2019-07-31	Agents as peptide agonists for glp1/glucagon/gip receptors
IL247834A0 (en)	2016-11-30	Exendin-4 derivatives as dual peptides that are glp-1/glucagon agonists
IL256748A (en)	2018-03-29	New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists
IL248013A0 (en)	2016-11-30	glp-1/glucagon agonists derived from exendin-4
GB2551945B (en)	2021-09-08	Novel GLP-1 receptor agonist peptides
EP3154956A4 (en)	2018-01-17	Glucagon antagonists
GB201811757D0 (en)	2018-08-29	Composition comprising GLP-1 receptor agonist and glucagon receptor agonist and application thereof
EP3329922A4 (en)	2019-03-27	SECRETAGOGUE OF GLP-1
IL265182A (en)	2019-05-30	proinsulin derivatives
HK1228923A1 (zh)	2017-11-10	衍生自毒蜥外泌肽-4的glp-1/胰高血糖素受体双重激动剂
HK1229341A1 (zh)	2017-11-17	作为肽性双重glp-1/胰高血糖素受体激动剂的毒蜥外泌肽-4衍生物
HK1231053A1 (zh)	2017-12-15	胰高血糖素拮抗剂
HK1235411A1 (zh)	2018-03-09	胰高血糖素和glp-1受体的共激动剂
HK1229340A1 (zh)	2017-11-17	衍生自毒蜥外泌肽-4的肽类双重glp-1/胰高血糖素受体激动剂